Prelude Therapeutics Incorporated
US ˙ NasdaqGS ˙ US74065P1012

Introduction

This page provides a comprehensive analysis of the known insider trading history of David J Mauro. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate David J Mauro has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:RXRX / Recursion Pharmaceuticals, Inc. Chief Medical Officer 225,429
US:CDAK / Codiak Biosciences Inc Chief Medical Officer 20,000
US:PRLD / Prelude Therapeutics Incorporated Chief Medical Officer 137,610
US:ADXS / Ayala Pharmaceuticals, Inc. Chief Medical Officer 166,271
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by David J Mauro. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases PRLD / Prelude Therapeutics Incorporated - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in PRLD / Prelude Therapeutics Incorporated. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PRLD / Prelude Therapeutics Incorporated Insider Trades
Insider Sales PRLD / Prelude Therapeutics Incorporated - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in PRLD / Prelude Therapeutics Incorporated. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PRLD / Prelude Therapeutics Incorporated Insider Trades
Insider Purchases RXRX / Recursion Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in PRLD / Prelude Therapeutics Incorporated. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RXRX / Recursion Pharmaceuticals, Inc. Insider Trades
Insider Sales RXRX / Recursion Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in PRLD / Prelude Therapeutics Incorporated. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RXRX / Recursion Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by David J Mauro as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-11-19 2024-11-15 4 RXRX RECURSION PHARMACEUTICALS, INC.
Class A Common Stock
F - Taxes -4,187 225,429 -1.82 6.18 -25,855 1,392,024
2024-08-19 2024-08-15 4 RXRX RECURSION PHARMACEUTICALS, INC.
Class A Common Stock
F - Taxes -14,146 229,616 -5.80 6.69 -94,637 1,536,131
2024-05-17 2024-05-15 4 RXRX RECURSION PHARMACEUTICALS, INC.
Class A Common Stock
F - Taxes -867 243,762 -0.35 10.01 -8,679 2,440,058
2024-02-13 2024-02-09 4 RXRX RECURSION PHARMACEUTICALS, INC.
Class A Common Stock
F - Taxes -1,892 244,629 -0.77 10.09 -19,090 2,468,307
2024-02-13 2024-02-09 4 RXRX RECURSION PHARMACEUTICALS, INC.
Class A Common Stock
A - Award 49,768 246,521 25.29
2024-02-13 2024-02-09 4 RXRX RECURSION PHARMACEUTICALS, INC.
Class A Common Stock
A - Award 6,040 196,753 3.17
2023-06-07 3 RXRX RECURSION PHARMACEUTICALS, INC.
No securities are beneficially owned.
0
2023-06-07 2023-06-01 4 RXRX RECURSION PHARMACEUTICALS, INC.
Class A Common Stock
A - Award 190,713 190,713
2022-05-04 2022-05-02 4 CDAK Codiak BioSciences, Inc.
Restricted Stock Units
A - Award 20,000 20,000
2022-05-04 2022-05-02 4 CDAK Codiak BioSciences, Inc.
Stock Option (Right to Buy)
A - Award 200,000 200,000
2021-10-06 2021-10-05 4 PRLD Prelude Therapeutics Inc
Employee Stock Option (Right to Buy)
M - Exercise -15,000 137,610 -9.83
2021-10-06 2021-10-05 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -1,289 0 -100.00 32.06 -41,330
2021-10-06 2021-10-05 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -7,803 1,289 -85.82 31.30 -244,257 40,350
2021-10-06 2021-10-05 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -5,908 9,092 -39.39 30.26 -178,762 275,103
2021-10-06 2021-10-05 4 PRLD Prelude Therapeutics Inc
Common Stock
M - Exercise 15,000 15,000 1.89 28,350 28,350
2021-09-09 2021-09-07 4 PRLD Prelude Therapeutics Inc
Employee Stock Option (Right to Buy)
M - Exercise -15,000 167,610 -8.21
2021-09-09 2021-09-07 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -4,640 0 -100.00 37.79 -175,334
2021-09-09 2021-09-07 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -2,873 4,640 -38.24 36.92 -106,081 171,325
2021-09-09 2021-09-07 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -7,487 7,513 -49.91 35.91 -268,867 269,801
2021-09-09 2021-09-07 4 PRLD Prelude Therapeutics Inc
Common Stock
M - Exercise 15,000 15,000 1.89 28,350 28,350
2021-08-09 2021-08-05 4 PRLD Prelude Therapeutics Inc
Employee Stock Option (Right to Buy)
M - Exercise -15,000 167,610 -8.21
2021-08-09 2021-08-05 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -100 0 -100.00 32.63 -3,263
2021-08-09 2021-08-05 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -6,721 100 -98.53 32.15 -216,051 3,215
2021-08-09 2021-08-05 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -2,063 6,821 -23.22 31.03 -64,010 211,641
2021-08-09 2021-08-05 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -6,116 8,884 -40.77 29.93 -183,070 265,924
2021-08-09 2021-08-05 4 PRLD Prelude Therapeutics Inc
Common Stock
M - Exercise 15,000 15,000 1.89 28,350 28,350
2021-07-22 2021-07-20 4 PRLD Prelude Therapeutics Inc
Employee Stock Option (Right to Buy)
A - Award 95,000 95,000
2021-07-08 2021-07-06 4 PRLD Prelude Therapeutics Inc
Employee Stock Option (Right to Buy)
M - Exercise -15,000 182,610 -7.59
2021-07-08 2021-07-06 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -300 0 -100.00 28.84 -8,653
2021-07-08 2021-07-06 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -4,255 300 -93.41 28.13 -119,711 8,440
2021-07-08 2021-07-06 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -10,445 4,555 -69.63 27.17 -283,743 123,738
2021-07-08 2021-07-06 4 PRLD Prelude Therapeutics Inc
Common Stock
M - Exercise 15,000 15,000 1.89 28,350 28,350
2021-06-09 2021-06-07 4 PRLD Prelude Therapeutics Inc
Common Stock
M - Exercise -15,000 197,610 -7.06
2021-06-09 2021-06-07 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -12,700 0 -100.00 32.73 -415,665
2021-06-09 2021-06-07 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -900 12,700 -6.62 31.62 -28,462 401,630
2021-06-09 2021-06-07 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -1,400 13,600 -9.33 30.35 -42,496 412,816
2021-06-09 2021-06-07 4 PRLD Prelude Therapeutics Inc
Common Stock
M - Exercise 15,000 15,000 1.89 28,350 28,350
2021-05-10 2021-05-05 4 PRLD Prelude Therapeutics Inc
Common Stock
M - Exercise -15,000 212,610 -6.59
2021-05-10 2021-05-05 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -1,109 0 -100.00 41.07 -45,545
2021-05-10 2021-05-05 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -10,476 1,109 -90.43 40.30 -422,148 44,689
2021-05-10 2021-05-05 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -3,415 11,585 -22.77 39.36 -134,399 455,933
2021-05-10 2021-05-05 4 PRLD Prelude Therapeutics Inc
Common Stock
M - Exercise 15,000 15,000 1.89 28,350 28,350
2021-04-29 2021-04-27 4 PRLD Prelude Therapeutics Inc
Employee Stock Option (right to buy)
M - Exercise -25,000 227,610 -9.90
2021-04-29 2021-04-27 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -1,711 0 -100.00 36.11 -61,791
2021-04-29 2021-04-27 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -15,601 1,711 -90.12 35.68 -556,580 61,041
2021-04-29 2021-04-27 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -7,688 17,312 -30.75 34.66 -266,478 600,060
2021-04-29 2021-04-27 4 PRLD Prelude Therapeutics Inc
Common Stock
M - Exercise 25,000 25,000 1.89 47,250 47,250
2021-04-21 2021-04-19 4 PRLD Prelude Therapeutics Inc
Employee Stock Option (right to buy)
M - Exercise -25,000 252,610 -9.01
2021-04-21 2021-04-19 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -4,000 0 -100.00 31.27 -125,077
2021-04-21 2021-04-19 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -21,000 4,000 -84.00 30.82 -647,272 123,290
2021-04-21 2021-04-19 4 PRLD Prelude Therapeutics Inc
Common Stock
M - Exercise 25,000 25,000 1.89 47,250 47,250
2021-04-15 2021-04-08 4 PRLD Prelude Therapeutics Inc
Employee Stock Option (right to buy)
M - Exercise -9,617 277,610 -3.35
2021-04-15 2021-04-08 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -3,549 0 -100.00 39.56 -140,393
2021-04-15 2021-04-08 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -1,293 3,549 -26.70 39.00 -50,423 138,401
2021-04-15 2021-04-08 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -1,501 4,842 -23.66 37.83 -56,780 183,165
2021-04-15 2021-04-08 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -3,274 6,343 -34.04 37.04 -121,256 234,919
2021-04-15 2021-04-08 4 PRLD Prelude Therapeutics Inc
Common Stock
M - Exercise 9,617 9,617 1.89 18,176 18,176
2021-04-09 2021-04-07 4 PRLD Prelude Therapeutics Inc
Employee Stock Option (right to buy)
M - Exercise -15,383 287,227 -5.08
2021-04-09 2021-04-07 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -7,083 0 -100.00 39.69 -281,116
2021-04-09 2021-04-07 4 PRLD Prelude Therapeutics Inc
Common Stock
S - Sale X -8,300 7,083 -53.96 39.02 -323,908 276,414
2021-04-09 2021-04-07 4 PRLD Prelude Therapeutics Inc
Common Stock
M - Exercise 15,383 15,383 1.89 29,074 29,074
2016-01-04 2015-12-31 4 ADXS Advaxis, Inc.
Common Stock
F - Taxes -41 166,271 -0.02 10.06 -412 1,672,686
2016-01-04 2015-12-31 4 ADXS Advaxis, Inc.
Common Stock
A - Award 195 166,312 0.12 10.06 1,962 1,673,099
2015-12-01 2015-11-30 4 ADXS Advaxis, Inc.
Common Stock
F - Taxes -18 166,118 -0.01 12.07 -217 2,005,044
2015-12-01 2015-11-30 4 ADXS Advaxis, Inc.
Common Stock
A - Award 108 166,136 0.07 12.07 1,304 2,005,262
2015-11-06 2015-11-05 4 ADXS Advaxis, Inc.
Options
A - Award 160,000 160,000
2015-11-03 2015-10-30 4 ADXS Advaxis, Inc.
Common Stock
F - Taxes -21 166,028 -0.01 11.09 -233 1,841,251
2015-11-03 2015-10-30 4 ADXS Advaxis, Inc.
Common Stock
A - Award 117 166,049 0.07 11.09 1,298 1,841,483
2015-10-22 2015-10-20 4 ADXS Advaxis, Inc.
Common Stock
S - Sale -24,586 165,932 -12.90 10.08 -247,827 1,672,595
2015-10-01 2015-09-30 4 ADXS Advaxis, Inc.
Common Stock
F - Taxes -23 190,518 -0.01 10.23 -235 1,948,999
2015-10-01 2015-09-30 4 ADXS Advaxis, Inc.
Common Stock
A - Award 127 190,541 0.07 10.23 1,299 1,949,234
2015-09-02 2015-08-31 4 ADXS Advaxis, Inc.
Common Stock
F - Taxes -16 190,414 -0.01 14.80 -237 2,818,127
2015-09-02 2015-08-31 4 ADXS Advaxis, Inc.
Common Stock
A - Award 88 190,430 0.05 14.80 1,302 2,818,364
2015-08-04 2015-07-31 4 ADXS Advaxis, Inc.
Common Stock
F - Taxes -25 190,342 -0.01 16.66 -416 3,171,098
2015-08-04 2015-07-31 4 ADXS Advaxis, Inc.
Common Stock
A - Award 117 190,367 0.06 16.66 1,949 3,171,514
2015-07-01 2015-06-30 4 ADXS Advaxis, Inc.
Common Stock
F - Taxes -12 190,250 -0.01 20.33 -244 3,867,782
2015-07-01 2015-06-30 4 ADXS Advaxis, Inc.
Common Stock
A - Award 64 190,262 0.03 20.33 1,301 3,868,026
2015-06-02 2015-05-29 4 ADXS Advaxis, Inc.
Common Stock
F - Taxes -9 190,198 0.00 25.16 -226 4,785,382
2015-06-02 2015-05-29 4 ADXS Advaxis, Inc.
Common Stock
A - Award 51 190,207 0.03 25.16 1,283 4,785,608
2015-05-01 2015-04-30 4 ADXS Advaxis, Inc.
Common Stock
F - Taxes -13 190,156 -0.01 16.81 -219 3,196,522
2015-05-01 2015-04-30 4 ADXS Advaxis, Inc.
Common Stock
A - Award 76 190,169 0.04 16.81 1,278 3,196,741
2015-04-01 2015-03-31 4 ADXS Advaxis, Inc.
Common Stock
F - Taxes -38 190,093 -0.02 14.44 -549 2,744,943
2015-04-01 2015-03-31 4 ADXS Advaxis, Inc.
Common Stock
A - Award 85 190,131 0.04 14.44 1,227 2,745,492
2015-04-01 2015-03-30 4 ADXS Advaxis, Inc.
Options
A - Award 110,220 110,220
2015-04-01 2015-03-30 4 ADXS Advaxis, Inc.
Common Stock
F - Taxes -6,062 190,046 -3.09 13.44 -81,473 2,554,218
2015-04-01 2015-03-30 4 ADXS Advaxis, Inc.
Common Stock
A - Award 55,110 196,108 39.09
2015-03-02 2015-02-27 4 ADXS Advaxis, Inc.
Common Stock
F - Taxes -32 140,998 -0.02 9.00 -288 1,268,982
2015-03-02 2015-02-27 4 ADXS Advaxis, Inc.
Common Stock
A - Award 136 141,030 0.10 9.00 1,224 1,269,270
2015-02-04 2015-01-30 4 ADXS Advaxis, Inc.
Common Stock
F - Taxes -59 140,894 -0.04 9.85 -581 1,387,806
2015-02-04 2015-01-30 4 ADXS Advaxis, Inc.
Common Stock
A - Award 186 140,953 0.13 9.85 1,832 1,388,387
2015-02-04 2014-12-10 4 ADXS Advaxis, Inc.
Common Stock
F - Taxes -4,817 140,767 -3.31 3.33 -16,041 468,754
2015-02-04 2014-12-10 4 ADXS Advaxis, Inc.
Common Stock
A - Award 9,796 145,584 7.21
2015-01-02 2014-12-31 4 ADXS Advaxis, Inc.
Common Stock
F - Taxes -25 135,788 -0.02 8.01 -200 1,087,662
2015-01-02 2014-12-31 4 ADXS Advaxis, Inc.
Common Stock
A - Award 151 135,813 0.11 8.01 1,210 1,087,862
2014-12-01 2014-11-28 4 ADXS Advaxis, Inc.
Common Stock
F - Taxes -61 135,662 -0.04 3.12 -190 423,265
2014-12-01 2014-11-28 4 ADXS Advaxis, Inc.
Common Stock
A - Award 388 135,723 0.29 3.12 1,211 423,456
2014-11-03 2014-10-31 4 ADXS Advaxis, Inc.
Common Stock
F - Taxes -25 135,335 -0.02 3.18 -80 430,365
2014-11-03 2014-10-31 4 ADXS Advaxis, Inc.
Common Stock
A - Award 190 135,360 0.14 3.18 604 430,445
2014-10-21 2014-10-20 4 ADXS Advaxis, Inc.
Common Stock
F - Taxes -29,830 135,170 -18.08 2.88 -85,910 389,290
2014-10-21 2014-10-20 4 ADXS Advaxis, Inc.
Common Stock
A - Award 165,000 165,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)